Physician profile
Tahseen Khan
NPI 1205828811
$766.37
in general payments reported to CMS, 2019-2025
15 companies · $126 in 2025
The $126 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $43.37 · 2021: $16.74 · 2022: $87.05 · 2023: $163 · 2024: $218 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $153.37 | 2019-2023 | Jornay Pm |
| Corium, LLC | $143.13 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $90.64 | 2019-2023 | Doc Band |
| Sanofi-Aventis U.S. LLC | $72.53 | 2024-2025 | |
| Tris Pharma INC | $67.18 | 2022-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $45.56 | 2022-2024 | Adzenys Xr-Odt |
| Pfizer INC. | $41.26 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $36.46 | 2023-2024 | Vaxelis, Gardasil 9, M-M-R II |
| Krystal Biotech INC | $23.89 | 2025 | Vyjuvek |
| Sobi, INC | $22.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $16.74 | 2021 | |
| Vertical Pharmaceuticals, LLC | $15.22 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.07 | 2025 | Qelbree |
| Shire North American Group INC | $12.46 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tahseen Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.